STK35

Serine/threonine-protein kinase 35

1,218 patent compounds predicted against STK35, 875 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL3193747	0.74	2/20
SCHEMBL3193752	0.74	2/20
SCHEMBL1227526	0.73	2/20
SCHEMBL1227708	0.71	2/20
SCHEMBL1227432	0.69	2/20
SCHEMBL1227471	0.68	2/20
SCHEMBL1227756	0.67	2/20
SCHEMBL1226728	0.66	2/20
SCHEMBL1227646	0.63	2/20
SCHEMBL1228195	0.63	2/20
SCHEMBL1401644	0.62	2/20
SCHEMBL1401645	0.62	2/20
SCHEMBL1401716	0.62	2/20
SCHEMBL1401718	0.62	2/20
SCHEMBL1401788	0.62	2/20
SCHEMBL1401789	0.62	2/20
SCHEMBL1401643	0.61	2/20
SCHEMBL1401686	0.61	2/20
SCHEMBL5605854	0.61	2/20
SCHEMBL3450442	0.57	2/20

Germline variants in STK35 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full STK35 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to STK35 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Signal TrAnsduction Pathway Activity Analysis in OVarian cancER	PHASE2/PHASE3	RECRUITING
Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy	PHASE2	COMPLETED
Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)	PHASE2	COMPLETED
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients	PHASE2	COMPLETED
Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma	PHASE2	UNKNOWN
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer	PHASE2	COMPLETED
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma	PHASE2	COMPLETED
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors	PHASE2	RECRUITING
Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor	PHASE2	ACTIVE_NOT_RECRUITING
FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers	PHASE1	RECRUITING
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors	PHASE1	RECRUITING
First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors	PHASE1	COMPLETED
A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).	PHASE1	ACTIVE_NOT_RECRUITING
A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors	PHASE1	UNKNOWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KN510, KN713	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
New Genes in the Carcinogenesis of Colorectal Cancer	nan	UNKNOWN
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases	nan	NOT_YET_RECRUITING
LRRK2 Activity and Markers of Parkinson's Disease in G2385R Carriers	nan	COMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Is There an Association Between Innate CD8+ T Cells and the Evolution of Tyrosine Kinase Inhibitor Resistance Mutations in Phi+ Hematological Malignancies.	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a STK35 binder may also engage these)

Protein	Name	Similarity
Q80ZW0	—	0.998	Q80ZW0 →
Q9BZ19	—	0.981	Q9BZ19 →
Q8CHE4	—	0.968	Q8CHE4 →
PHLPP1	PH domain leucine-rich repeat-containing protein phosphatase 1	0.968	landscape →
Q80Z30	—	0.968	Q80Z30 →
Q9WTR8	—	0.967	Q9WTR8 →
PDE10A	cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	0.967	landscape →
Q2TBI2	—	0.967	Q2TBI2 →
Q8K0Z9	—	0.966	Q8K0Z9 →
Q9WU40	—	0.966	Q9WU40 →
Q8WY91	—	0.965	Q8WY91 →
Q62925	—	0.964	Q62925 →
Q5QP82	—	0.964	Q5QP82 →
Q9P2K9	—	0.963	Q9P2K9 →
Q9UF56	—	0.963	Q9UF56 →
O00221	—	0.962	O00221 →
Q8VCC6	—	0.962	Q8VCC6 →
Q6NS60	—	0.962	Q6NS60 →
D3YYI7	—	0.961	D3YYI7 →
Q75VX8	—	0.961	Q75VX8 →
Q9QZN1	—	0.961	Q9QZN1 →
Q8TF61	—	0.961	Q8TF61 →
Q3UN16	—	0.961	Q3UN16 →
Q86SH2	—	0.961	Q86SH2 →
A2AKB9	—	0.961	A2AKB9 →
WEE1	Wee1-like protein kinase	0.960	landscape →
Q9CUB6	—	0.960	Q9CUB6 →
P39881	—	0.960	P39881 →
Q6ZW76	—	0.960	Q6ZW76 →
Q5VV17	—	0.960	Q5VV17 →